A trade deal has been struck with 11 countries on both sides of the Pacific, including Canada.
For smaller countries, access to the U.S. market is a major prize.
Donald Trump doesn’t understand the benefits of trade, and Hillary Clinton has criticized trade on the campaign trail.
America's place as a world leader in economic freedom has faltered.
Companies might relocate production capacity from the U.S. to Canada to gain duty-free access to the Chinese domestic market.
Canada's lagging intellectual property (IP) protections for pharmaceutical innovators are a key issue to be settled in the Comprehensive Economic and Trade Agreement (CETA) negotiations with the European Union. They may also play a role in upcoming negotiations for the multi-country Trans-Pacific Partnership (TPP). Two new essays on the cost and benefits of stronger protection suggest Canadians would be far better off, in both economic and health terms, with an IP protection regime for pharmaceutical innovators that was more closely aligned with international standards.
Trade and Economic Benefits of Enhanced Intellectual Property Protection for Pharmaceuticals in Canada
There are few Canadians who understand agricultural supply management and how it affects their daily lives, which is a major reason why this outdated system has survived. Its receiving greater scrutiny now, though, because its impeding trade agreements.